Zura Bio's High Stakes Gamble on Tibulizumab Zura Bio's latest quarterly report has left investors and industry watchers perplexed by its continued pursuit of tibulizumab in multiple clinical trials.
The company's ability to enroll patients ahead of schedule is a testament to its operational prowess, but it also underscores the significant risks associated with developing a single molecule for multiple indications.
Tibulizumab has shown promise in treating various autoimmune diseases by blocking both interleukin 17 and B cell activating factor.